Table 1:
Baseline characteristics of participants in outcomes study
| Full cohort (n=293) | No cardiovascular event (n=271) | Cardiovascular event (n=22) | p value (event vs no event) | |
|---|---|---|---|---|
| Median age, years (IQR) | 55.0 (45.0–65.5) | 55.0 (44.0–64.0) | 64.5 (60.0–78.3) | <0.0001 |
| Male | 124 (42%) | 111 (41%) | 13 (59%) | 0.10 |
| White race | 271 (93%) | 243 (89%) | 20 (91%) | 0.85 |
| Current smoker | 27 (9%) | 20 (7%) | 7 (32%) | 0.0001 |
| Hypertension | 103 (35%) | 89 (32%) | 14 (64%) | 0.0035 |
| Diabetes mellitus | 25 (8%) | 19 (7%) | 6 (27%) | 0.0010 |
| Hyperlipidaemia | 85 (29%) | 74 (27%) | 11 (50 %) | 0.0241 |
| Mean total cholesterol (SD) | 190.7 (47.4) | 193.4 (47.9) | 174.6 (42.1) | 0.10 |
| Mean LDL cholesterol (SD) | 109.6 (38.9) | 111.4 (39.2) | 98.6 (36.2) | 0.17 |
| Statin therapy | 61 (21%) | 51 (19%) | 10 (46%) | 0.0030 |
| Mean Framingham risk score (SD) | 5.9 (6.2) | 5.1 (5.9) | 10.6 (5.9) | 0.0002 |
| Median body-mass index (IQR) | 26.8 (23.4–31.0) | 26.6 (23.2–30.9) | 27.0 (24.8–32.6) | 0.36 |
| Coronary artery calcium score | .. | .. | 0.0012 | |
| 0–10 | 204 (70%) | 192 (71%) | 12 (55%) | .. |
| 11–99 | 39 (13%) | 33 (12%) | 6 (27%) | .. |
| ≥100 | 33 (11%) | 29 (11%) | 4 (18 %) | .. |
| History of cancer | 256 (87%) | 241 (89%) | 15 (68%) | 0.0114 |
| Previous chemotherapy | 234 (80%) | 221 (82%) | 13 (59%) | 0.0047 |
| History of depression or anxiety* | 29 (10%) | 25 (9%) | 4 (20%) | 0.13 |
| Antidepressant drug use* | 27 (9%) | 24 (9%) | 3 (15%) | 0.42 |
Data are n (%), unless otherwise specified. The coronary artery calcium score is a measure derived from coronary CT. The presence of calcium in the coronary artery suggests the presence of coronary atherosclerotic disease.
*
Data for depression and anxiety and for antidepressant drug use were available for 288 participants—268 in the no events group and 20 in the cardiovascular disease events group.